GARIN1A: A Potential Drug Target and Biomarker for Golgi-associated Rab2 Interactor 1A

Target Name: GARIN1A

NCBI ID: G346653

GARIN1A

GARIN1A: A Potential Drug Target and Biomarker for Golgi-associated Rab2 Interactor 1A

Golgi-associated Rab2 interactor 1A (GARIN1A) is a protein that is expressed in various tissues and cell types, including the brain, pancreas, and gastrointestinal tract. It is a member of the Rab2 family of G protein-coupled receptors, which are involved in various cellular signaling pathways. GARIN1A has been shown to play a role in the regulation of cellular processes that are relevant to a variety of diseases, including neurodegenerative disorders, cancer, and gastrointestinal diseases. As a result, GARIN1A has potential as a drug target or biomarker.

GARIN1A is a 12-kDa protein that is expressed in the brain, pancreas, and gastrointestinal tract. It is highly conserved across various species, with a calculated pI of 4.87. GARIN1A is associated with the Rab2 family of G protein-coupled receptors, which are known for their role in intracellular signaling pathways. The Rab2 family of G protein-coupled receptors is a subset of the large G protein-coupled receptor family 2 (GPCR), which includes over 700 different proteins.

GARIN1A has been shown to play a role in the regulation of various cellular processes that are relevant to a variety of diseases, including neurodegenerative disorders, cancer, and gastrointestinal diseases. For example, GARIN1A has been shown to be involved in the regulation of neurotransmitter release from axons in the central nervous system, which is relevant to the treatment of neurodegenerative disorders such as Alzheimer's disease. In addition, GARIN1A has been shown to be involved in the regulation of insulin secretion from pancreatic beta cells, which is relevant to the treatment of diabetes.

In addition to its potential role in the regulation of cellular processes, GARIN1A has also been shown to be a potential drug target. GARIN1A has been shown to interact with various small molecules, including drugs that are currently being used to treat various diseases. For example , GARIN1A has been shown to interact with rapamycin, a drug that is used to treat cancer and other diseases. In addition, GARIN1A has been shown to interact with various proteins that are involved in cellular signaling pathways, including the protein p21 (TKF1), which is a negative regulator of the interview/DNA-binding domain.

GARIN1A is also a potential biomarker for a variety of diseases. For example, GARIN1A has been shown to be expressed in various tissues and cell types, including the brain, pancreas, and gastrointestinal tract. This suggests that GARIN1A may be a useful biomarker for diseases that affect these tissues. In addition, GARIN1A has been shown to be involved in the regulation of cellular processes that are relevant to a variety of diseases, including neurodegenerative disorders, cancer, and gastrointestinal diseases. This suggests that GARIN1A may be a useful biomarker for diseases that affect these processes.

In conclusion, GARIN1A is a protein that is expressed in various tissues and cell types, including the brain, pancreas, and gastrointestinal tract. It is a member of the Rab2 family of G protein-coupled receptors and has been shown to play a role in the regulation of various cellular processes that are relevant to a variety of diseases, including neurodegenerative disorders, cancer, and gastrointestinal diseases. As a result, GARIN1A has potential as a drug target or biomarker. Further research is needed to fully understand the role of GARIN1A in

Protein Name: Golgi Associated RAB2 Interactor 1A

Functions: RAB2B effector protein required for accurate acrosome formation and normal male fertility

The "GARIN1A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GARIN1A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets